NASDAQ:AMED - Amedisys Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $289.00
Forecasted Upside: 9.47 %
Number of Analysts: 11
Breakdown:
0 Sell Ratings
2 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$264.00 As of 07/23/2021 01:00 AM ET

▲ +5.73 (2.22%)

1 month | 3 months | 12 months

Get New Amedisys Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for AMED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMED

^$289.00

▲ +9.47% Upside Potential

This price target is based on 11 analysts offering 12 month price targets for Amedisys in the last 3 months. The average price target is $289.00, with a high forecast of $350.00 and a low forecast of $245.00. The average price target represents a 9.47% upside from the last price of $264.00.

Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in Amedisys. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
10 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
9 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
9 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/30/2021	Royal Bank of Canada	Boost Price Target	Outperform	$335.00 ➝ $350.00	High
2/23/2021	Benchmark	Boost Price Target	Positive ➝ Buy	$275.00 ➝ $325.00	Medium
2/8/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$275.00 ➝ $340.00	Medium
1/5/2021	Truist	Boost Price Target		$280.00 ➝ $325.00	N/A
11/3/2020	Barclays	Boost Price Target	Overweight	$290.00 ➝ $298.00	Medium
10/30/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$260.00 ➝ $275.00	High
10/30/2020	Credit Suisse Group	Boost Price Target	Outperform	$246.00 ➝ $280.00	High
9/21/2020	Oppenheimer	Boost Price Target	Outperform	$250.00 ➝ $260.00	High
9/10/2020	Stephens	Reiterated Rating	Equal Weight	$235.00 ➝ $245.00	Medium
9/2/2020	BMO Capital Markets	Boost Price Target	Market Perform	$250.00 ➝ $270.00	High
8/20/2020	Barclays	Initiated Coverage	Overweight	$290.00 ➝ $290.00	High
7/30/2020	SunTrust Banks	Boost Price Target	Buy	$260.00 ➝ $270.00	Medium
7/30/2020	Benchmark	Boost Price Target	Buy	$210.00 ➝ $250.00	Medium
7/30/2020	Royal Bank of Canada	Boost Price Target	Outperform	$218.00 ➝ $260.00	Medium
7/30/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$220.00 ➝ $260.00	Medium
7/30/2020	Raymond James	Boost Price Target	Outperform	$210.00 ➝ $255.00	Medium
7/29/2020	Jefferies Financial Group	Boost Price Target	Buy	$225.00 ➝ $250.00	Medium
7/10/2020	SunTrust Banks	Boost Price Target	Buy	$240.00 ➝ $260.00	Medium
6/18/2020	Benchmark	Upgrade	Hold ➝ Buy	$210.00	High
5/21/2020	SunTrust Banks	Boost Price Target	Buy	$225.00 ➝ $240.00	High
5/11/2020	UBS Group	Lower Price Target	Neutral	$208.00 ➝ $190.00	Low
5/11/2020	Raymond James	Lower Price Target	Outperform	$225.00 ➝ $210.00	Medium
5/10/2020	Royal Bank of Canada	Reiterated Rating	Buy	$218.00	Medium
5/7/2020	Benchmark	Downgrade	Buy ➝ Hold		High
4/27/2020	Oppenheimer	Reiterated Rating	Buy	$215.00	Medium
3/9/2020	Benchmark	Upgrade	Hold ➝ Buy	$205.00	High
2/21/2020	Stephens	Boost Price Target	Equal Weight	$180.00 ➝ $200.00	Low
2/21/2020	UBS Group	Boost Price Target	Neutral	$154.00 ➝ $208.00	Low
2/21/2020	BMO Capital Markets	Reiterated Rating	Market Perform	$215.00	Low
2/21/2020	Credit Suisse Group	Boost Price Target	Outperform	$206.00 ➝ $214.00	Low
2/20/2020	SunTrust Banks	Boost Price Target	Buy	$185.00 ➝ $225.00	Low
2/20/2020	Raymond James	Boost Price Target	Outperform	$200.00 ➝ $225.00	Low
1/17/2020	Credit Suisse Group	Initiated Coverage	Outperform	$206.00	Low
1/3/2020	Raymond James	Set Price Target	Outperform	$144.00 ➝ $200.00	Medium
12/18/2019	SunTrust Banks	Boost Price Target	Buy	$175.00 ➝ $185.00	Low
12/6/2019	BMO Capital Markets	Initiated Coverage	Market Perform	$170.00	Medium
11/26/2019	Bank of America	Boost Price Target	Buy	$170.00 ➝ $178.00	Low
11/1/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$140.00 ➝ $160.00	High
10/22/2019	Stephens	Reiterated Rating	Equal Weight	$145.00	Low
10/21/2019	Stephens	Initiated Coverage	Equal Weight	$145.00	Low
9/16/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$155.00	Low
8/5/2019	Barclays	Boost Price Target	Equal Weight	$120.00 ➝ $125.00	High
8/2/2019	Royal Bank of Canada	Boost Price Target	Outperform	$150.00	Low
8/1/2019	Oppenheimer	Boost Price Target		$140.00 ➝ $150.00	Low
7/15/2019	Raymond James	Boost Price Target	Outperform	$140.00 ➝ $144.00	Medium
7/8/2019	Jefferies Financial Group	Set Price Target	Buy	$150.00	Low
5/2/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$140.00	High
3/21/2019	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$115.00 ➝ $120.00	Low
3/1/2019	Craig Hallum	Lower Price Target	Hold	$132.00 ➝ $124.00	Low
3/1/2019	SunTrust Banks	Boost Price Target	Buy	$145.00	Low
2/5/2019	Benchmark	Downgrade	Buy ➝ Hold	$136.64	High
12/14/2018	Barclays	Initiated Coverage	Equal Weight ➝ Equal Weight	$130.00	High
11/16/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$126.00	Medium
10/30/2018	Benchmark	Upgrade	Hold ➝ Buy	$125.00	High
10/26/2018	Craig Hallum	Downgrade	Buy ➝ Hold	$116.00 ➝ $104.00	Medium
10/11/2018	Robert W. Baird	Boost Price Target	Neutral	$105.00 ➝ $120.00	High
10/11/2018	SunTrust Banks	Boost Price Target	Buy	$130.00	High
10/11/2018	Cantor Fitzgerald	Boost Price Target	Neutral	$117.00 ➝ $125.00	High
9/18/2018	Bank of America	Set Price Target	Buy	$139.00	Low
9/13/2018	Cantor Fitzgerald	Initiated Coverage	Neutral	$117.00	Low
9/13/2018	Canaccord Genuity	Initiated Coverage	Neutral	$117.00	Low
8/3/2018	Royal Bank of Canada	Boost Price Target	Outperform	$115.00	Medium
7/3/2018	Bank of America	Upgrade	Neutral ➝ Buy	$88.00 ➝ $97.00	Medium
6/5/2018	Bank of America	Boost Price Target	Neutral ➝ Neutral	$73.00 ➝ $78.00	Medium
6/5/2018	Stephens	Reiterated Rating	Hold	$78.00	High
6/5/2018	Robert W. Baird	Boost Price Target	Neutral ➝ Neutral	$67.00 ➝ $72.00	High
5/9/2018	Craig Hallum	Boost Price Target	Buy	$60.00 ➝ $82.00	Low
5/8/2018	Robert W. Baird	Boost Price Target	Neutral ➝ Neutral	$66.00	High
3/19/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform		Low
3/1/2018	Robert W. Baird	Set Price Target	Neutral ➝ Hold	$60.00 ➝ $66.00	Medium
3/1/2018	Oppenheimer	Boost Price Target	Outperform	$68.00 ➝ $63.00	High
2/28/2018	Jefferies Financial Group	Set Price Target	Buy	$70.00	Medium
11/21/2017	William Blair	Reiterated Rating	Outperform		N/A
11/10/2017	SunTrust Banks	Reiterated Rating	Buy	$70.00	N/A
11/10/2017	Robert W. Baird	Boost Price Target	Neutral	$50.00 ➝ $60.00	N/A
11/9/2017	Craig Hallum	Reiterated Rating	Buy	$55.00 ➝ $68.00	N/A
11/9/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$56.00 ➝ $62.00	N/A
11/9/2017	Benchmark	Reiterated Rating	Buy ➝ Hold		N/A
11/8/2017	Mizuho	Reiterated Rating	Buy	$55.00 ➝ $65.00	N/A
11/2/2017	Benchmark	Upgrade	Hold ➝ Buy	$56.00	N/A
11/2/2017	Mizuho	Upgrade	Neutral ➝ Buy	$55.00 ➝ $65.00	N/A
10/23/2017	Royal Bank of Canada	Reiterated Rating	Hold		N/A
10/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$60.00	N/A
10/9/2017	SunTrust Banks	Reiterated Rating	Buy	$60.00	N/A
10/4/2017	Robert W. Baird	Reiterated Rating	Hold	$50.00	Low
9/15/2017	Oppenheimer	Reiterated Rating	Buy	$60.00	Low
8/21/2017	Bank of America	Initiated Coverage	Neutral ➝ Neutral	$55.00	Low
7/26/2017	Mizuho	Downgrade	Buy ➝ Neutral	$50.00	High
6/5/2017	Royal Bank of Canada	Reiterated Rating	Hold	$56.00	Low
5/4/2017	Stephens	Boost Price Target	Equal Weight	$50.00 ➝ $54.00	Low
5/3/2017	Benchmark	Reiterated Rating	Hold ➝ Hold	$50.00 ➝ $57.00	High
5/3/2017	Mizuho	Upgrade	Neutral ➝ Buy	$65.00	High
4/28/2017	Jefferies Financial Group	Reiterated Rating	Buy	$57.00	Low
3/3/2017	Oppenheimer	Reiterated Rating	Outperform	$50.00 ➝ $59.00	N/A
3/1/2017	Jefferies Financial Group	Boost Price Target	Buy	$50.00 ➝ $57.00	N/A
3/1/2017	Mizuho	Boost Price Target	Neutral ➝ Neutral	$33.00 ➝ $50.00	N/A
1/27/2017	Benchmark	Initiated Coverage	Hold	$50.00	N/A
1/17/2017	Craig Hallum	Set Price Target	Buy	$60.00	N/A
1/13/2017	Jefferies Financial Group	Set Price Target	Buy	$50.00	N/A
12/16/2016	Craig Hallum	Initiated Coverage	Buy	$48.00	N/A
11/9/2016	Mizuho	Downgrade	Buy ➝ Neutral		N/A
11/7/2016	Mizuho	Upgrade	Neutral ➝ Buy	$47.00	N/A
11/4/2016	Mizuho	Upgrade	Neutral ➝ Buy	$47.00	N/A
11/1/2016	Jefferies Financial Group	Reiterated Rating	Buy	$59.00 ➝ $50.00	N/A
9/11/2016	Wells Fargo & Company	Reiterated Rating	Buy		N/A
9/6/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A
8/3/2016	Mizuho	Downgrade	Buy ➝ Neutral	$57.00 ➝ $55.00	N/A

(Data available from 7/25/2016 forward)

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. As of December 31, 2020, the company owned and operated 320 home health care centers, 180 hospice care centers, and 14 personal-care care centers in 39 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Today's Range

Now: $264.00

$257.04

$265.01

50 Day Range

MA: $256.22

$238.97

$270.32

52 Week Range

Now: $264.00

$212.99

$325.12

Volume

186,819 shs

Average Volume

245,761 shs

Market Capitalization

$8.60 billion

P/E Ratio

43.56

Dividend Yield

N/A

Beta

0.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Amedisys?

The following Wall Street sell-side analysts have issued reports on Amedisys in the last year: Barclays PLC, Benchmark Co., BMO Capital Markets, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stephens, SunTrust Banks, Inc., Truist, and Zacks Investment Research.
View the latest analyst ratings for AMED.

What is the current price target for Amedisys?

12 Wall Street analysts have set twelve-month price targets for Amedisys in the last year. Their average twelve-month price target is $289.00, suggesting a possible upside of 9.5%. Royal Bank of Canada has the highest price target set, predicting AMED will reach $350.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $245.00 for Amedisys in the next year.
View the latest price targets for AMED.

What is the current consensus analyst rating for Amedisys?

Amedisys currently has 2 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMED will outperform the market and that investors should add to their positions of Amedisys.
View the latest ratings for AMED.

What other companies compete with Amedisys?

Other companies that are similar to Amedisys include Laboratory Co. of America, Quest Diagnostics, DaVita, Chemed, LHC Group, R1 RCM, AMN Healthcare Services, MEDNAX, CorVel, Tivity Health and Cross Country Healthcare.

How do I contact Amedisys' investor relations team?

Amedisys' physical mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider's listed phone number is 225-292-2031 and its investor relations email address is [email protected] The official website for Amedisys is www.amedisys.com.